FGEN FibroGen Inc.

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.

FibroGen’s management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit . 

For Investor Inquiries:

David DeLucia, CFA

Senior Vice President and Chief Financial Officer



EN
02/04/2025

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare ...

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. FibroGen’s management team will be available for one-on-one meetings on Wednesday, April 9th. Interested investors should contact their representative at Needham. About FibroGen FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer bi...

April 2, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
XPL SOLITARIO ZINC
WYNN Wynn Resorts L... ... (+52)

InsiderInsights Weekly Report: March 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

XPL SOLITARIO ZINC
WYNN WYNN RESORTS LIMITED
ULTA ULTA BEAUTY INC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TITN TITAN MACHINERY
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
OMCL OMNICELL INC.
MG MISTRAS GROUP
MEI METHODE ELECTRONICS INC.
MCHX MARCHEX INC. CL B
IMMR IMMERSION CORP.
HSC HARSCO CORPORATION
GOGO GOGO INC.
GCO GENESCO INC.
FGEN FIBROGEN INC.
CFFN CAPITOL FEDERAL FINANCIAL INC.
AHH ARMADA HOFFLER PROPERTIES INC.
ADBE ADOBE INC.
OPRX OPTIMIZERX CORP
QRHC QUEST RESOURCE HOLDING
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
ECC EAGLE POINT CREDIT CO INC
GCBC GREENE COUNTY BANCORP INC.
HI HILLENBRAND INC.
LIVE LIVE VENTURES
BV BRIGHTVIEW HOLDINGS
HFFG HF FOODS GROUP INC
TROX TRONOX HOLDINGS PLC
AEYE AUDIOEYE INC
ZYME ZYMEWORKS INC.
GRWG GROWGENERATION
PRLD PRELUDE THERAPEUTICS
FTHM FATHOM HOLDINGS
IMNM IMMUNOME
LYEL LYELL IMMUNOPHARMA INC
TOI ONCOLOGY INSTITUTE INC (THE)
HD HOME DEPOT
BTMD INC.
BLIN HAYMAKER ACQUISITION CORP III
BUKS BRIDGELINE DIGITAL INC
MODD BUTLER NATIONAL CORP
MLYS MODULAR MEDICAL INC
WEST MINERALYS THERAPEUTICS INC
SRFM WESTROCK COFFEE COMPANY LLC
GUTS SURF AIR MOBILITY INC.
ADVM FRACTYL HEALTH INC
AFCG ADVERUM BIOTECHNOLOGIES INC.
FG AFC GAMMA
EU INC.
F AND G ANNUITIES AND LIFE
INC.
WISDOMTREE EURO DEBT FUND
03/29/25 March 29, 2025 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

FibroGen Announces Publication of Results from Phase 1 Monotherapy Stu...

FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancerInitiation of Phase 2 monotherapy dose optimization study of FG-3246 in mCRPC expected by mid-2025 SAN FRANCISCO, March 28, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the peer-reviewed publication titled in the Journal of Clinical Onc...

March 28, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
WYNN Wynn Resorts L...
TITN TITAN MACHINERY ... (+11)

InsiderInsights.com Daily Ratings Report: March 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

WYNN WYNN RESORTS LIMITED
TITN TITAN MACHINERY
STAA STAAR SURGICAL CO.
PSEC PROSPECT CAPITAL CORPORATION
FGEN FIBROGEN INC.
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
IMNM IMMUNOME
LYEL LYELL IMMUNOPHARMA INC
FG F AND G ANNUITIES AND LIFE
INC.
03/25/25 March 25, 2025 1 EN
Free Trial
FGEN FIBROGEN INC.

Fibrogen Inc: 1 director

A director at Fibrogen Inc bought 300,000 shares at 0.350USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

03/24/25 March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch